Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease

Gut

Volumn 53, Issue 8, 2004, Pages 1123-1128

  Wright, S ^b   Sanders, D S ^a   Lobo, A J ^a   Lennard, L ^a,b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; THIOGUANOSINE;

ARTICLE; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; REMISSION; STEADY STATE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; ERYTHROCYTES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; THIOGUANINE; TREATMENT OUTCOME;

EID: 3242732900     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.032896     Document Type: Article

References (37)

1. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-9.
2. Lobo AJ, Foster PN, Burke DA, et al. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990;33:374-7.
3. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6MP and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
4. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2.
5. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997;112:1475-81.
6. Elion GB, Callahan SW, Hitchings GH, et al. The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazoyl)thiopurine] (BW-57-323) in man. Cancer Chemother 1960;8:47-52.
7. Chalmers AH. Studies on the mechanism of formation of 5-mercapto-1-methyl-4-nitroimidazole. A metabolite of the immunosuppressive drug azathioprine. Biochem pharmacol 1974;23:1891-901.
8. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
9. Tidd DM, Paterson ARP. Distiction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34:738-46.
10. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
11. Dubinsky MC, Yang HY, Hassard PV, et al. 6-mercaptopurine metabolite profiles provide a biochemical explanation to 6-mercaptopurine resistance in patients with inflammatory bowel disease. Gut 2002;122:904-15.
12. Weinshilboum RM. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001;29:601-5.
13. Lennard L, Lilleyman JS, Van Loon JA, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
14. Evans WE, Horner MH, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphoblastic leukaemia. J Pediatr 1991;119:885-9.
15. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343:1188-90.
16. Lennard L, Davis H, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993;68:186-90.
17. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
18. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
19. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis, 2001;7:181-89.
20. Herrlinger KR, Kreisel W, Schwab M, et al. 6-Thioguanine - efficiency and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003;17:503-8.
21. Gupta P, Gokhale R, Kirschner BS. 6-Mercaptopurine levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:450-4.
22. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70.
23. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51:143-6.
24. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.
25. Walmsley RS, Ayres RCS, Pounder RE, et al. A simple clinical colitis activity index. Gut 1998;43:29-32.
26. Lennard L, Singleton HJ. High performance liquid chromatographic assay of the methyl and nucleotide metabolites af 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatog 1992;583:83-90.
27. McLeod HL, Relling MV, Liu Q, et al. Polymorphic TPMT in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukaemia. Blood 1995;85:1897-902.
28. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000;14:1009-14.
29. Hoffmann M, Rychlewski J, Chrzanowska M, et al. Mechanism of activation of an immunosuppressive drug: azathioprine. Quantum chemical study on the reaction of azathioprine with cysteine. J Am Chem Soc 2001;123:6404-9.
30. Richards GA, Van Antwerpen VL, Hunter S, et al. Aging and cigarette smoke are associated with decreased glutathione levels in humans. S Afr J Sci, 1996;92:445-7.
31. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scand J Gastroenterol 2001;36:71-6.
32. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a passible indicator of compliance? Br J Cancer 1995;72:1004-6.
33. Wright EC. Non-compliance - or how many aunts has matilda? Lancet 1993;342:909-13.
34. Nevins TE, Kruse LK, Skeans MA, et al. The natural history of azathioprine compliance after renal transplantation. Kidney Int, 2001;60:1565-70.
35. Davis HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance. BMJ 1993;72:1004-6.
36. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.
37. Lowry PW, Szumlanski CL, Weinshilboum RM, et al. Balsalazide and azathioprine or 6-mercaptopurine: Evidence for a potentially serious drug interaction. Gastroenterology 1999;116:1505-6.